Activity

Each mutation type, categorized as positive, invariably caused a degree of anemia, ranging from mild to moderate.

The most frequent genetic mutation identified among Sudanese beta-thalassemia patients, according to the research findings, is the IVS-1-110 mutation. Mild to moderate anemia resulted from each positive mutation type.

The last two decades have witnessed a substantial transformation of the myeloproliferative neoplasms (MPNs) research field. A systematic review of the existing literature is undertaken in this study with the goal of producing novel approaches for MPN scientific research.

Utilizing CiteSpace and VOSviewer, a bibliometric analysis of MPN research was undertaken to unveil the developmental trajectory, pivotal research topics, and frontier advancements in clinical practice, mechanisms, and management strategies related to MPN.

1807 academic journals served as platforms for 11922 papers, the product of 1099 authors hailing from 736 institutions in 113 countries/regions. In this research domain, Italy and the United States held prominent positions. No other institution produces as many publications as the Mayo Clinic. The act of active cooperation has been restricted to only a few countries and institutions. icg-001 inhibitor Ayalew Tefferi and Ruben A. Mesa are acknowledged as significant and exceptional contributors to the field. Based on the volume and impact of their publications and citations, Blood and Leukemia journals are considered influential. Regarding MPN research within this field, the central focus is understanding the onset and progression of MPN itself, the clinical significance of alterations in non-driving genes, improving the effectiveness of initial and subsequent anti-thrombotic measures, investigating the clinical application of long-acting interferons and JAK2 inhibitors, and discovering improved therapeutic strategies for myelofibrosis (both primary and secondary forms) and post-MPN acute myeloid leukemia (AML).

Rapid development characterizes the current stage of the research. Significant room exists for enhancing collaboration among various institutions and countries (or regions). Myeloproliferative neoplasms (MPN) research is heavily concentrated, as determined by hotspot analysis, on areas like gene mutations, thrombotic occurrences, new drug applications, disease progression patterns, and other linked issues.

Rapid progress characterizes the current stage of the research. The existing partnerships between diverse institutions and countries (regions) offer a foundation for future growth and development. The hotspot analysis of MPN research underscores the significance of gene mutations, thrombosis, the introduction of novel medications, disease progression, and other crucial subjects.

Our study investigated the possible relationship between fibrinogen levels in the blood of patients hospitalized for acute cholecystitis (AC) with conservative therapy at our clinic. Following surgical procedures, patients were given medical care and sent home.

From January 2018 to February 2020, a prospective record was made of the files belonging to 118 patients hospitalized at our clinic for AC, with the intention of conservative medical care. Patients were sorted into two groups based on their response to conservative treatment. Group 1 comprised those who responded favorably to the conservative approach; Group 2 comprised those requiring immediate surgical intervention, even after conservative treatment attempts. A diagnosis of acute cholecystitis was supported by the ultrasound and CT findings, which included a thickened gallbladder wall, pericholecystic fluid, and a hydrops sac. Fibrinogen levels in the blood were determined for every patient throughout their period of hospitalization.

In a study involving 118 patients, their mean age was determined to be 5832 years, with a minimum of 19 and a maximum of 96 years. Group 1 contained 77 patients and Group 2 contained 41 patients, resulting in differing serum fibrinogen levels. Group 1 showed a level of 29,834,111.7 mg/dL, and Group 2 showed a level of 6,371,245 mg/dL, demonstrating a statistically significant difference (p<0.0001). In the context of surgical interventions, when the fibrinogen level surpassed 56450 mg/dL, the test’s sensitivity was 756% and specificity was 61%.

The findings of our study point to the necessity of considering the need for surgery, even alongside medical treatment, when evaluating data from patients with acute cholecystitis and high plasma fibrinogen levels at initial presentation.

Our research has shown that a critical component in evaluating collected data is the urgent surgical need for patients with acute cholecystitis and elevated plasma fibrinogen levels (cutoff) upon initial evaluation, irrespective of initial medical treatment.

Conventional coagulation tests (CCTs) are commonplace in sepsis patients, yet their limitations prevent the identification of hypercoagulation. Moreover, coagulation cascade tests (CCTs) err in identifying hypocoagulation, resulting in a rise in unnecessary blood transfusions. Thus, we aimed to utilize rotational thromboelastometry (ROTEM) to categorize the coagulation status of sepsis patients with abnormal clot contraction times (CCTs), to determine the key coagulation components contributing to the coagulation state.

In an observational study designed to examine ROTEM use in 161 sepsis patients meeting Sepsis-3 criteria, this research was integrated. The University Medical Center, Ho Chi Minh City, performed concurrent Comprehensive Critical Care Trials (CCT) and Rapid Optimization of Transfusion Efficacy (ROTEM) assessments on ICU patients admitted from June 2020 to December 2021, all within a 24-hour timeframe. Data selection in this study was restricted to patients experiencing sepsis and having abnormalities observed on their computed tomography (CT) scans. This included metrics like activated partial thromboplastin time ratio, international normalized ratio (INR), platelet count, and fibrinogen concentration.

Seventy-nine patients presenting with sepsis and exhibiting abnormal CCTs averaged 69 years of age, and 487% of this patient population were women. Of the 34 patients, each having an INR of 16, ROTEM analysis showcased 118% exhibiting hypercoagulation, and 206% exhibiting normal coagulation patterns. In a cohort of 29 patients with platelet counts of fewer than 100 (103/mm3), ROTEM results indicated hypercoagulation in 35% and normal coagulation in 241%. The hypercoagulability group, defined by ROTEM, displayed a maximum clot firmness elevation in 95.1% of the subjects; this group also exhibited significantly greater plasma fibrinogen levels compared to other groups (p<0.0005).

Sepsis patients with hypocoagulation, as observed in CCTs, may show signs of hypercoagulability upon ROTEM assessment. Hyperfibrinogenemia, a condition present in sepsis patients, is associated with hypercoagulation.

Hypercoagulability, potentially masked by hypocoagulation, can be detected in sepsis patients through the use of ROTEM, informed by CCT findings. Hyperfibrinogenemia, a condition characterized by elevated fibrinogen levels, is a contributing factor to hypercoagulation in patients suffering from sepsis.

We planned to assess whether plasma monocyte chemotactic protein-1 (MCP-1), fetuin-A, serum total antioxidant status (TAS), and serum total oxidant status (TOS) act as cardiac biomarkers in acute myocardial infarction (AMI), and to clarify the connection between each.

Ninety participants were involved in the study, comprising 60 patients with AMI (30 exhibiting and 30 lacking ST-segment elevation myocardial infarction (STEMI)), and an additional 30 cardiac patients without AMI. A statistical evaluation was conducted to assess the diagnostic utility of serum Hs-cTnT, MCP-1, fetuin-A, TAS, and TOS levels in identifying acute myocardial infarction (AMI).

The study found that median levels of MCP-1 (12010 ng/L, interquartile range 7694-23054 ng/L) and TOS (289 U/MI, IQR 231-394 U/Ml) were significantly higher, and median levels of fetuin-A (43352 mg/L, IQR 38789-58449 mg/L) and TAS (310,086 U/mL) were lower in patients with AMI compared to the control group. Fetuin-A exhibited the parameter values—area under the curve (0815), sensitivity (733%), and specificity (667%)—most similar to those of Hs-cTnT, followed by MCP-1, TOS, and TAS in descending order of similarity. A one-unit increase in circulating MCP-1 levels was significantly (p = 0.002) linked to a 1023-fold greater probability of experiencing AMI. A one-unit augmentation in fetuin-A levels was correlated with a 0.995-fold decrease in the likelihood of developing acute myocardial infarction (AMI), a statistically meaningful result (p = 0.003). A one-unit elevation in serum TOS levels was associated with a 129-fold greater likelihood of STEMI compared to NSTEMI (p = 0.0044).

In the early diagnosis of AMI, Hs-cTnT levels could be augmented by the presence of MCP-1, oxidative stress parameters, and fetuin-A. Potential independent risk factors for AMI are Fetuin-A and MCP-1 levels, and TOS may assist in the clinical distinction between STEMI and NSTEMI.

A possible link between MCP-1, oxidative stress parameters, fetuin-A, and Hs-cTnT levels exists, potentially enabling earlier detection of AMI. While Fetuin-A and MCP-1 levels may independently elevate the risk of AMI, TOS could offer a method for differentiating between STEMI and NSTEMI cases.

The escalating number of deaths globally due to cerebrovascular diseases (CVDs) maintains their significance as a substantial public health problem. The physiopathology of CVDs might be better understood by examining changes in peptide synthesis and release. The study’s objective was to ascertain the levels of maresin-1 (MaR-1), subfatin (SUB), asprosin (ASP), and alamandine (ALA) among patients with cerebral infarction (CI), intracranial hemorrhage (ICH), or subarachnoid hemorrhage (SAH), all categorized under cardiovascular diseases (CVDs), compared to a group of healthy individuals.

Four groups of study participants were constituted: CI patients, ICH patients, SAH patients, and healthy volunteers. Using the National Institutes of Health Stroke Scale (NIHSS), Intracerebral Hemorrhage Score (ICHS), Botterel-Hunt-Hess Scale (BHHS), and cranial computed tomography (CT), CVDs were diagnosed.